Modulation of Gut Microbiota by Probiotic in Children With Respiratory Symptoms
Respiratory Infection (for Example, Pneumonia, Bronchitis)
About this trial
This is an interventional treatment trial for Respiratory Infection (for Example, Pneumonia, Bronchitis) focused on measuring probiotic, respiratory tract infections, Bifidobacterium, children
Eligibility Criteria
Inclusion Criteria: Preschool children (>12 months old, <7 years old). Having respiratory symptoms (having at least two of the following signs and symptoms: fever (even if only reported not measured), nasal obstruction, chills, sore throat, headache, cough, runny nose, olfactory disturbances, or taste disturbances; Pucarelli-Lebreiro et al., 2022). Healthy with current weight of P20-P80 percentile chart of children Infant formula powder does not contain probiotics; prebiotics FOS is not allowed, GOS <2g/ 100g is allowed Willing to commit throughout the experiment Exclusion Criteria: Long term medication >6 months for any diseases Deformity Mothers with metabolic and/or chronic diseases Current or previous diseases, conditions or interventions that may interfere with the study (such as tolerance and/or growth and development), such as gastrointestinal malformations, chronic diarrhea, malabsorption syndromes, malnutrition, congenital immunodeficiency or surgery Oral antibiotics within 2 weeks before the intervention Nutritional supplements containing probiotics and prebiotics (except infant formula) within 2 weeks before the intervention Foods for special medical purposes or non-standard formula powders for lactose intolerance and galactosemia Probiotic allergies or possible food allergies (milk, etc.) Participated in other clinical studies 4 weeks before the intervention Unwilling to participate for any particular reason
Sites / Locations
- UKM Medical CentreRecruiting
Arms of the Study
Arm 1
Arm 2
Experimental
Placebo Comparator
Probiotic
Placebo
Bifidobacterium infantis YLGB-1496 at 1x10 log CFU/day for 12 weeks
Intervention consists of daily administration of 2g of maltodextrin, administered daily for 12-weeks)